Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma

Trial Profile

Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Aspirin; Ipilimumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top